The combination of CDK12 KO and TP53 KD may not mimic aggressive phenotype seen in clinical CDK12 LOF prostate cancer.Yuki Kamiyama,Tomohiro Fukui,Takuro Sunada,Hiroko Kimura,Takayuki Goto,Takashi Kobayashi,Shusuke AkamatsuCANCER SCIENCE(2022)引用 0|浏览11暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要